MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

ACADIA Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

22.56 -0.18

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

22.4

Massimo

22.82

Metriche Chiave

By Trading Economics

Entrata

-125M

19M

Vendite

-15M

244M

P/E

Media del settore

15.978

39.857

Margine di Profitto

7.771

Dipendenti

653

EBITDA

7.1M

19M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+28.87% upside

Dividendi

By Dow Jones

Utili prossimi

5 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

374M

3.7B

Apertura precedente

22.74

Chiusura precedente

22.56

Notizie sul Sentiment di mercato

By Acuity

34%

66%

108 / 376 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

ACADIA Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 lug 2025, 23:34 UTC

Acquisizioni, Fusioni, Takeovers

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17 lug 2025, 21:14 UTC

Acquisizioni, Fusioni, Takeovers

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17 lug 2025, 21:04 UTC

I principali Market Mover
Acquisizioni, Fusioni, Takeovers

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17 lug 2025, 23:43 UTC

Discorsi di Mercato

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17 lug 2025, 23:42 UTC

Discorsi di Mercato

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17 lug 2025, 22:47 UTC

Acquisizioni, Fusioni, Takeovers

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17 lug 2025, 22:46 UTC

Acquisizioni, Fusioni, Takeovers

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17 lug 2025, 22:46 UTC

Acquisizioni, Fusioni, Takeovers

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17 lug 2025, 22:43 UTC

Acquisizioni, Fusioni, Takeovers

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17 lug 2025, 22:43 UTC

Acquisizioni, Fusioni, Takeovers

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17 lug 2025, 22:40 UTC

Acquisizioni, Fusioni, Takeovers

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 lug 2025, 22:40 UTC

Acquisizioni, Fusioni, Takeovers

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 lug 2025, 22:30 UTC

Discorsi di Mercato
Utili

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17 lug 2025, 22:20 UTC

Discorsi di Mercato
Utili

Global Equities Roundup: Market Talk

17 lug 2025, 22:20 UTC

Discorsi di Mercato
Utili

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17 lug 2025, 22:04 UTC

Discorsi di Mercato
Utili

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17 lug 2025, 22:03 UTC

Acquisizioni, Fusioni, Takeovers

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17 lug 2025, 21:58 UTC

Discorsi di Mercato
Utili

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17 lug 2025, 21:57 UTC

Utili

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 lug 2025, 21:47 UTC

Utili

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17 lug 2025, 21:45 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

17 lug 2025, 21:45 UTC

Discorsi di Mercato

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17 lug 2025, 21:38 UTC

Acquisizioni, Fusioni, Takeovers

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17 lug 2025, 21:22 UTC

Acquisizioni, Fusioni, Takeovers

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 lug 2025, 21:05 UTC

Utili

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 lug 2025, 21:04 UTC

Acquisizioni, Fusioni, Takeovers

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17 lug 2025, 21:02 UTC

Acquisizioni, Fusioni, Takeovers

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 lug 2025, 20:59 UTC

Acquisizioni, Fusioni, Takeovers

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17 lug 2025, 20:50 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

17 lug 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

ACADIA Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

28.87% in crescita

Previsioni per 12 mesi

Media 29.06 USD  28.87%

Alto 39 USD

Basso 15 USD

Basato su 19 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per ACADIA Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

19 ratings

13

Acquista

5

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

14.845 / N/ASupporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Strong Bearish Evidence

A lungo termine

Neutral Evidence

Sentiment

By Acuity

108 / 376 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.